Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102713 · ClinicalTrials.gov registry record · Phase 3
A Study for Treatment of Partial Seizures in Children
A Phase 3 study of Partial Seizures, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 10
- Study locations
NCT00102713 is a Phase 3 study of Partial Seizures that has completed, run by Abbott. The registered enrollment target is 50 participants. The trial reports 10 study locations across 8 states.
The verdict
NCT00102713, a Phase 3 study of Partial Seizures, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of the study is to assess the safety profile of the investigational medication, Depakote Sprinkle Capsules, in the treatment of partial seizures in children ages 3-10.
Conditions Studied
Interventions
- DRUG Divalproex Sodium (Depakote Sprinkle Capsules)
Study Locations (10)
Ohio
- Akron Children's Hospital - Akron
- University Hospitals of Cleveland - Cleveland
Virginia
- Monarch Medical Research - Norfolk
- Virginia Commonwealth University Medical Center - Richmond
Alabama
- Neurology Clinic, P.C. - Northport
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Florida
- Pediatric Epilepsy and Neurology Specialists - Tampa
Georgia
- Child Neurology Associates, P.C. - Atlanta
Texas
- Texas Association of Pediatric Neurology, P.A. - San Antonio
Wisconsin
- Richard V. Colan, M.D., S.C. - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102713
The ClinicalTrials.gov registry entry for NCT00102713 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Partial Seizures appearing as the primary indexed condition, and to 1 intervention - of which Divalproex Sodium (Depakote Sprinkle Capsules) is the first listed.
NCT00102713 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Ohio, Virginia, Alabama.
Frequently Asked Questions
What is clinical trial NCT00102713 about?
NCT00102713 is a clinical study titled "A Study for Treatment of Partial Seizures in Children". The purpose of the study is to assess the safety profile of the investigational medication, Depakote Sprinkle Capsules, in the treatment of partial seizures in children ages 3-10.
What is the current status of trial NCT00102713?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2005-02.
What conditions does trial NCT00102713 study?
This clinical trial studies the following conditions: Partial Seizures.
What interventions are being tested in trial NCT00102713?
The interventions under investigation include: Divalproex Sodium (Depakote Sprinkle Capsules) (DRUG).
Who is sponsoring clinical trial NCT00102713?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00102713 being conducted?
This trial has 10 study locations across Alabama, Arizona, Florida, Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.